6369 related articles for article (PubMed ID: 1300752)
1. [The cellular immunity indices of patients with malignant melanoma using the viral immunomodulator rigvir].
Glinkina LS; Bruvere RZh; Venskus DR; Garklava RR; Muceniece AJ
Vopr Onkol; 1992; 38(5):540-7. PubMed ID: 1300752
[TBL] [Abstract][Full Text] [Related]
2. [The humoral immunity indices of patients with malignant skin melanoma using the viral immunomodulator rigvir].
Glinkina LS; Heisele OG; Garklava RR; Muceniece AJ
Vopr Onkol; 1992; 38(5):534-40. PubMed ID: 1300751
[TBL] [Abstract][Full Text] [Related]
3. [The reaction of the T-immunity system in patients with malignant skin melanoma and stomach cancer to active nonspecific immunotherapy].
Glinkina LS; Bruvere RZh
Vopr Onkol; 1992; 38(6):659-66. PubMed ID: 1300766
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of T- and B-cell immunity of regional lymph nodes in patients with skin melanoma and prognosis of the disease].
Serov AA; Kadagidze ZG
Vopr Onkol; 1983; 29(12):18-20. PubMed ID: 6607569
[TBL] [Abstract][Full Text] [Related]
5. Some aspects of cell-mediated hypersensitivity in patients with melanoma.
Moszkowska G; Jassem J; Kondrat W; Kopacz A; Goszczyńska E
Arch Immunol Ther Exp (Warsz); 1980; 28(4):655-60. PubMed ID: 6970028
[TBL] [Abstract][Full Text] [Related]
6. Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma.
Killock D
Nat Rev Clin Oncol; 2015 Aug; 12(8):438. PubMed ID: 26077044
[No Abstract] [Full Text] [Related]
7. Thymosin-inducible lymphocytes in the peripheral blood of patients with malignant melanoma.
Byrom NA; Campbell MA; Dean AJ; Timlin DM; Volkers C; Bodenham DC; Hobbs JR
Cancer Treat Rep; 1978 Nov; 62(11):1769-74. PubMed ID: 310343
[TBL] [Abstract][Full Text] [Related]
8. [Disorders of immune system function and their correction in melanomas with regional metastases].
Labunets IF; Grinevich IuA; Tolstopiatov BA
Vopr Onkol; 1989; 35(4):416-23. PubMed ID: 2728381
[TBL] [Abstract][Full Text] [Related]
9. [The effect of immunocorrective preparations on the cellular immunity indices of patients with recurrent respiratory diseases].
Bychkova NH; Marushenko IuV; Son'kin VM
Lik Sprava; 1999 Jul; (5):46-9. PubMed ID: 10822676
[TBL] [Abstract][Full Text] [Related]
10. [A comparison of the morphofunctional characteristics of the peripheral blood lymphocytes and the immune status of patients with malignant melanoma of the skin].
Naleskina LA; Ganina KP; Labunets IF; Grinevich IuA; Abramenko VA
Tsitol Genet; 1996; 30(5):16-22. PubMed ID: 9026985
[TBL] [Abstract][Full Text] [Related]
11. [Dynamics of immunologic indices in patients with Kaposi's sarcoma during treatment with the preparation leakadine].
Gorshkova NI; Samsonov VA; Mazina NM; Parastaev SA
Vestn Dermatol Venerol; 1989; (9):6-10. PubMed ID: 2609769
[TBL] [Abstract][Full Text] [Related]
12. Cimetidine in malignant melanoma.
Timm EG; Rozek SL
DICP; 1989 Sep; 23(9):689-91. PubMed ID: 2800583
[No Abstract] [Full Text] [Related]
13. Serum-mediated blocking of cell-mediated anti-tumor immunity in a melanoma patient: association with BCG immunotherapy and clinical deterioration.
Levy NL; Mahaley MS; Day ED
Int J Cancer; 1972 Sep; 10(2):244-8. PubMed ID: 4661092
[No Abstract] [Full Text] [Related]
14. Vaccination and melanoma risk.
Pfahlberg A; Botev IN; Kölmel KF; Gefeller O
Int J Cancer; 2002 Nov; 102(1):96-7. PubMed ID: 12353240
[No Abstract] [Full Text] [Related]
15. Effects of large doses of dialysable leukocyte extract.
Khan A; Benjamin C; Antonetti A; Hill JM
Proc Soc Exp Biol Med; 1980 Oct; 165(1):91-5. PubMed ID: 6968440
[No Abstract] [Full Text] [Related]
16. [Immune reactivity and in vitro effect of levamisole in a group of patients with malignant melanoma].
Sansoni P; Rossetti A; Valente G; Butturini U
Boll Ist Sieroter Milan; 1982 Mar; 61(1):51-7. PubMed ID: 6982048
[No Abstract] [Full Text] [Related]
17. [Thymopentin in the treatment of cutaneous melanoma].
Trevisan G; Agolzer A
G Ital Dermatol Venereol; 1989 May; 124(5):245-9. PubMed ID: 2695455
[TBL] [Abstract][Full Text] [Related]
18. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy of taktivin in patients with viral myocarditis and dilated cardiomyopathy].
Kipshidze NN; Dzhaparidze MM; Dzidziguri LM; Rachvelishvili NB; Dateshidze MN; Demetrashvili MF
Ter Arkh; 1990; 62(9):116-8. PubMed ID: 2177920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
